BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Roche seeks alpha to defeat Novartis
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
